From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases .
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4, κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .
CD22 ligand-1 (compound 12) is a potent and selective CD22 ligand with KD of 0.335, 30.7 µM for hCD22 and MAG, respectively. CD22 ligand-1 has the potential for the research of B-cell related disease .
CD22 Human Pre-designed siRNA Set A contains three designed siRNAs for CD22 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Anti-CD22-NMS249 is a CD22-targeting antibody-drug conjugate (ADC). Anti-CD22-NMS249 is composed of a humanized anti-CD22 antibody Pinatuzumab (HY-P99230), a cleavable linker (Mc-VC-PAB), and a DNA topoisomerase II inhibitor payload PNU-159682 (HY-16700). Anti-CD22-NMS249 can be used for research in non-Hodgkin lymphoma (NHL) .
Pinatuzumab is a CD22 monoclonal antibody. Pinatuzumab targets the cell-surface antigen CD22. Pinatuzumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including non-Hodgkin lymphoma (NHL) .
Moxetumomab pasudotox (CAT 8015) is anti-CD22 immunotoxin containing an anti-CD22 Fv and Pseudomonas exotoxin. CD22 is a cell surface receptor expressed on a variety of malignant B-cells. Moxetumomab pasudotox can be used in the research of hairy cell leukemia (HCL) .
Mc-Val-Cit-PAB-Cl is a cleavable ADC linker. Mc-Val-Cit-PAB-Cl can be used to conjugate MMAE and antibody to form antibody-MC-vc-MMAE (e.g., anti-CD22-MC-VC-PABC-MMAE with IC50s of 3.3 and 0.95 nM for BJAB and WSU cell lines in cytotoxicity assay).
Bectumomab (IMMU-LL 2) is an humanized IgG2a mAb against human CD22 (antigen). Bectumomab is also an anti-lymphoma antibody fragment. Bectumomab can be used for imaging in combination with technetium 99 (Tc99m LL2 Fab). Moreover, Bectumomab examines in the staging of recurrent or newly diagnosed non-Hodgkin's lymphoma (NHL) and to assess targeting before radioimmunoresearch (RIT) .
Ac4ManNDAz is a cell-permeable photocross-linking probe. Ac4ManNDAz can effectively compete with endogenous sialic acid for incorporation into cell surface glycoproteins and form cross-links with glycoprotein ligands under UV light irradiation. Ac4ManNDAz can be used to study interactions between glycoproteins .
Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases .
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4, κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .
Pinatuzumab is a CD22 monoclonal antibody. Pinatuzumab targets the cell-surface antigen CD22. Pinatuzumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including non-Hodgkin lymphoma (NHL) .
Moxetumomab pasudotox (CAT 8015) is anti-CD22 immunotoxin containing an anti-CD22 Fv and Pseudomonas exotoxin. CD22 is a cell surface receptor expressed on a variety of malignant B-cells. Moxetumomab pasudotox can be used in the research of hairy cell leukemia (HCL) .
Bectumomab (IMMU-LL 2) is an humanized IgG2a mAb against human CD22 (antigen). Bectumomab is also an anti-lymphoma antibody fragment. Bectumomab can be used for imaging in combination with technetium 99 (Tc99m LL2 Fab). Moreover, Bectumomab examines in the staging of recurrent or newly diagnosed non-Hodgkin's lymphoma (NHL) and to assess targeting before radioimmunoresearch (RIT) .
Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases .
The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues.It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface.CD22 Protein, Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived CD22 protein, expressed by HEK293 , with C-His labeled tag.
The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. Siglec-2/CD22 Protein, Human (HEK293, His) is the recombinant human-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-6*His labeled tag.
Siglec-2/CD22 Protein mediates B-cell B-cell interaction and may be involved in the localization of B-cells in lymphoid tissues. Siglec-2/CD22 Protein, Mouse (AAA02562.1, HEK293, His) is the recombinant mouse-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of Siglec-2/CD22 Protein, Mouse (AAA02562.1, HEK293, His) is 681 a.a., with molecular weight of 100-120 kDa.
The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues.It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface.CD22 Protein, Rhesus Macaque (HEK293, Fc) is the recombinant Rhesus Macaque-derived CD22 protein, expressed by HEK293 , with C-hFc labeled tag.
The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. Siglec-2/CD22 Protein, Human (668a.a, HEK293, Fc) is the recombinant human-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of Siglec-2/CD22 Protein, Human (668a.a, HEK293, Fc) is 668 a.a., with molecular weight of 120-150 kDa.
The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. Siglec-2/CD22 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag. The total length of Siglec-2/CD22 Protein, Human (Biotinylated, HEK293, His-Avi) is 668 a.a., with molecular weight of 110-130 kDa.
The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. Siglec-2/CD22 Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-His labeled tag. The total length of Siglec-2/CD22 Protein, Human (Biotinylated, HEK293, His) is 687 a.a., with molecular weight of ~76.6 KDa.
The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. Siglec-2/CD22 Protein, Rat (692a.a, HEK293, His) is the recombinant rat-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-His labeled tag. The total length of Siglec-2/CD22 Protein, Rat (692a.a, HEK293, His) is 692 a.a., with molecular weight of ~76.7 kDa.
The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. Siglec-2/CD22 Protein, Rat (692a.a, HEK293, Fc) is the recombinant rat-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of Siglec-2/CD22 Protein, Rat (692a.a, HEK293, Fc) is 692 a.a., with molecular weight of ~102 kDa.
Siglec-2/CD22 Protein, Mouse (690a.a, HEK293, Fc) is a Siglec of ~140 kDa with seven Ig-like domains and is expressed in a B-cell lineage-specific fashion, starting at the pre-B cell stage. CD22 is associated with membrane-bound IgM on the surface of B cells. Siglec-2 (CD22) specifically recognizes 伪2.6 sialic acid-containing glycans. Siglec-2 negatively regulates B cell antigen receptor (BCR) signaling by recruitment and activation of SH2-containing phosphatase 1 (SHP-1), which counteracts the phospharylation-mediated activation of signaling molecules by dephosphorylation, and reduces Ca2+ signaling by regulating the activity of the Ca2+ pump PMCA. Siglec-2/CD22 Protein, Mouse (690a.a, HEK293, Fc) is the recombinant mouse-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of Siglec-2/CD22 Protein, Mouse (690a.a, HEK293, Fc) is 690 a.a., with molecular weight of ~125 kDa.
The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. Siglec-2/CD22 Protein, Human (512a.a, HEK293, His) is the recombinant human-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-His labeled tag. The total length of Siglec-2/CD22 Protein, Human (512a.a, HEK293, His) is 512 a.a., with molecular weight of 90-100 kDa.
The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. Siglec-2/CD22 Protein, Human (Biotinylated, 512a.a, HEK293, His) is the recombinant human-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-His labeled tag. The total length of Siglec-2/CD22 Protein, Human (Biotinylated, 512a.a, HEK293, His) is 512 a.a., with molecular weight of ~58.5 KDa.
Siglec-2/CD22 Protein mediates B-cell interactions, potentially guiding B-cell localization within lymphoid tissues. Recognizing sialylated glycoproteins, especially alpha-2,6-linked sialic acid, it engages in cis interactions on the cell surface. During the immune response, ligand-induced tyrosine phosphorylation suggests its role in B-cell antigen receptor signaling. Siglec-2/CD22 acts positively through Src kinases and inhibits by recruiting phosphatases. Existing as a monomer or heterodimer, its interactions with key molecules highlight a pivotal role in complex B-cell signaling. Further research is essential for precise molecular pathways and functional consequences. Siglec-2/CD22 Protein, Human (FITC, HEK293, Fc) is the recombinant human-derived Siglec-2/CD22 protein, expressed by HEK293, with C-hFc labeled tag. The total length of Siglec-2/CD22 Protein, Human (FITC, HEK293, Fc) is 668 a.a., with molecular weight of 130-140 kDa.
The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. Siglec-2/CD22 Protein, Rhesus macaque (HEK293, His) is the recombinant Rhesus Macaque-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-His labeled tag. The total length of Siglec-2/CD22 Protein, Rhesus macaque (HEK293, His) is 667 a.a., with molecular weight of 100-120 kDa.
Siglec-2/CD22 is a B cell surface receptor that mediates B cell interactions and is involved in B cell localization within lymphoid tissues. It selectively binds α-2,6-linked sialic acids, including CD45, and its sialic acid recognition site may be regulated by cis interactions. Siglec-2/CD22 Protein, Mouse (HEK293, His) is the recombinant mouse-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of Siglec-2/CD22 Protein, Mouse (HEK293, His) is 681 a.a., with molecular weight of 95-130 kDa.
Siglec-2/CD22, a B-cell surface receptor, mediates B-cell interactions and participates in B-cell localization within lymphoid tissues. It selectively binds alpha-2,6-linked sialic acid, including CD45, with its sialic acid recognition site potentially regulated by cis interactions. In the immune response, ligand-induced tyrosine phosphorylation suggests a role in B-cell antigen receptor signaling modulation. It engages in both positive and inhibitory regulation by interacting with Src family kinases and recruiting cytoplasmic phosphatases via their SH2 domains. Interactions include LYN, SYK, PIK3R1/PIK3R2, PLCG1, SHC1, INPP5D, and GRB2 upon phosphorylation, as well as PTPN6/SHP-1 upon phosphorylation. Siglec-2/CD22 Protein, Mouse (Biotinylated, HEK293, His) is the recombinant mouse-derived Siglec-2/CD22 protein, expressed by HEK293 , with His labeled tag. The total length of Siglec-2/CD22 Protein, Mouse (Biotinylated, HEK293, His) is 681 a.a., with molecular weight of 90-110 kDa.
CD22 Antibody (YA1267) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1267), targeting CD22. CD22 Antibody (YA1267) can be used for IHC-P experiment in human background.
CD22 Human Pre-designed siRNA Set A contains three designed siRNAs for CD22 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Inquiry Online
Your information is safe with us. * Required Fields.
